Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $350.00 Price Target at Oppenheimer

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective decreased by Oppenheimer from $500.00 to $350.00 in a research note released on Friday morning,Benzinga reports. Oppenheimer currently has an outperform rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also commented on the stock. Royal Bank Of Canada decreased their target price on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating on the stock in a research report on Friday, May 1st. Stifel Nicolaus cut their price target on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating for the company in a report on Friday. HC Wainwright reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Friday. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 25th. Finally, Truist Financial lowered their target price on shares of Alnylam Pharmaceuticals from $505.00 to $410.00 and set a “buy” rating on the stock in a research report on Monday, July 13th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $410.72.

Alnylam Pharmaceuticals Stock Up 0.0%

Alnylam Pharmaceuticals stock opened at $205.52 on Friday. The stock’s 50 day moving average price is $287.96 and its 200 day moving average price is $311.32. Alnylam Pharmaceuticals has a 1-year low of $197.81 and a 1-year high of $495.55. The company has a market cap of $27.44 billion, a PE ratio of 38.20 and a beta of 0.27. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a return on equity of 104.81% and a net margin of 15.26%.The firm had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter in the prior year, the business posted ($0.44) earnings per share. Alnylam Pharmaceuticals’s revenue was up 96.4% compared to the same quarter last year. On average, sell-side analysts predict that Alnylam Pharmaceuticals will post 7.35 EPS for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the transaction, the director owned 1,582 shares of the company’s stock, valued at $473,302.76. The trade was a 70.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. MV Capital Management Inc. acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth about $25,000. HM Payson & Co. acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $27,000. Golden State Wealth Management LLC grew its position in shares of Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 36 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $29,000. Finally, Manchester Capital Management LLC increased its stake in shares of Alnylam Pharmaceuticals by 600.0% during the 4th quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 72 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Key Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Chardan Capital reaffirmed its Buy rating and assigned a $425 price target, while JPMorgan, RBC, Oppenheimer, and Stifel maintained bullish ratings despite lowering their targets. The revised targets remain well above the current trading level. Analyst ratings and price targets
• Positive Sentiment: Alnylam reported continued strength in its transthyretin franchise, including record quarterly Amvuttra sales, and revenue increased substantially from the prior-year period. These results support the company’s underlying commercial momentum. Alnylam Q2 2026 earnings call
• Neutral Sentiment: Analysts broadly lowered their targets: JPMorgan cut its target to $375, RBC to $350, Oppenheimer to $350, Stifel to $318, Wells Fargo to $316, and Morgan Stanley to $300. Ratings range from Buy/Outperform to Equal Weight, indicating optimism about valuation but greater near-term uncertainty. Analyst price-target changes
• Negative Sentiment: Second-quarter adjusted earnings of $1.84 per share exceeded some consensus measures but missed the $2.05 Zacks estimate, while revenue of $1.29 billion fell short of the roughly $1.32 billion consensus. Alnylam Q2 earnings miss
• Negative Sentiment: The company cut its 2026 product-revenue outlook to $5.3 billion-$5.7 billion, reflecting normalization in second-line Amvuttra demand and headwinds affecting the ATTR-CM market. The guidance reduction is the primary catalyst behind the stock’s decline. Alnylam lowers 2026 outlook
• Negative Sentiment: Several law firms announced securities-fraud investigations following the results and guidance cut. These announcements may add reputational and legal overhang, although they do not establish wrongdoing. Securities-fraud investigation

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.